source
- Evommune pays $30 million upfront to license Hinova’s oral molecular glue degrader for autoimmune pipelineEvommune announced a deal with Hinova Pharmaceuticals to license an oral molecular glue degrader aimed at autoimmune diseases. The agreement includes a $30 million upfront payment, split into $20…
- Madrigal’s 2024 MASH drug sparks new wave of diagnosis and personalized treatment approachesThe article argues that the field of metabolic dysfunction‑associated steatohepatitis (MASH) is entering a period of rapid innovation, and that the industry must broaden efforts in diagnosis, monit…